- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
- Contact Us
Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and located in Palo Alto, Calif., to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood.
Medivir, a research-based pharmaceutical company based in Sweden, and Cancer Research Technology (CRT), Cancer Research U.K.’s commercialization and development arm, have partnered to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer.
The circumstances of a recent pre-study assessment visit were unexpectedly touching, and productive, considering the absence of a Study Coordinator (SC).
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Status: Recruiting, Condition Summary: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
A new series of training videos for practicing clinical and community pharmacists
Parexel International, a global biopharmaceutical services provider, has announced three new academic programs at the Parexel Academy. The offerings span the globe and are designed to prepare students for careers in the biopharmaceutical industry. They include:
BioXcel, a Branford, Conn.-based provider of cloud-based pharma big data solutions for discovering novel products, has partnered with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. The awardee institutions will develop tools to identify certain pathogens that frequently cause infections in health care settings and, specifically, those that are resistant to most antimicrobials. Advancing the development of rapid and innovative diagnostic tests for identifying and characterizing resistant bacteria is a key goal of the President’s recent National Action Plan for Combating Antibiotic-Resistant Bacteria.
Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.
Eisai Inc., a U.S. subsidiary of Eisai Co., a global R&D-based pharmaceutical company headquartered in Japan, plans to restructure its operations in the U.S., including a reduction of its workforce by approximately 25% across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.
Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain, has appointed Lisa Nolan, Ph.D., as senior vice president of business development. Nolan will be responsible for overseeing alliance and business development activities across the company.
Margaret A. Hamburg, former commissioner of the FDA, has been appointed as the next foreign secretary of the Institute of Medicine, the health arm of the National Academy of Sciences. In this part-time position, Hamburg will work as a senior adviser on international matters to the IOM president and council and as liaison to foreign academies of medicine and science.
Updated statistics and exclusivity determinations list.
The FDA has accepted for filing Shire's NDA for lifitegrast and granted a Priority Review designation. Lifitegrast is an investigational treatment for dry eye disease in adults and, if approved, has the potential to be the first treatment indicated to address both signs and symptoms of the disease. The FDA is expected to provide a decision on October 25, based on the Prescription Drug User Fee Act V action date.
EnteroMedics, a developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, has named Scott A. Shikora, M.D., FACS, executive vice president of medical affairs and chief medical officer of EnteroMedics, effective June 1. He will lead the company's medical affairs, clinical and regulatory functions.
Greenphire, a provider of payment technology for the clinical trials industry, has moved its operations to new headquarters in King of Prussia, Pa. The move quadruples the company's office space in the region and supports Greenphire's ongoing growth strategy that will see the business rapidly scale its operational infrastructure to support its growing global client base.
Sanford-Burnham Medical Research Institute, a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego, Calif., and Orlando, Fla., has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.
Inovio Pharmaceuticals, based in Plymouth Meeting, Pa., has been awarded a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.
Roche has become a majority shareholder of Foundation Medicine, a molecular information company based in Cambridge, Mass. Roche purchased approximately 15.6 million shares of common stock through a tender offer from Foundation Medicine stockholders at a price of $50 per share.